Bank of Nova Scotia’s Regenxbio RGNX Stock Holding History

Bank of Nova Scotia’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,473	Closed	-$252K	–	1187
2025 Q4	$252K	Buy	+17,473	New	+$218K	﹤0.01%	1023

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Nova Scotia's RGNX Position: Q1 2026 in Review

Bank of Nova Scotia sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 17,473 shares — an estimated $252K sold.

Bank of Nova Scotia first reported a position in RGNX in Q4 2025 and held it in 1 quarter. The position peaked at $252K in Q4 2025. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Bank of Nova Scotia reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
Bank of Nova Scotia sold 17,473 Regenxbio shares in Q1 2026, an estimated $252K.
Bank of Nova Scotia first reported a position in Regenxbio in Q4 2025 and held it in 1 quarter.
Bank of Nova Scotia's Regenxbio position peaked at $252K in Q4 2025.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Bank of Nova Scotia's 13F filing for Q1 2026, filed 14 May 2026.